FTSE 100 logs first monthly gain in three; AstraZeneca jumps
The FTSE 100 rose 0.1% to 10,729.78, gaining over 1% in October, its first monthly increase in three months. AstraZeneca led gains, jumping 7% after announcing a restructuring plan. Banks weighed on the index, with NatWest falling 9%. BP rose 0.5% after reporting a record quarterly profit. The budget's softer-than-expected tax measures supported investor sentiment.
How this was made

The 30-second read
Why it matters
AstraZeneca's restructuring is the primary catalyst, lifting pharma and broader market sentiment, while NatWest's weak outlook drags banks.
Market read
UK equities rally on pharma news; sector‑specific moves create trading opportunities in AZN, BP, and banks.
What to watch
Potential regulatory or pipeline risks for AstraZeneca not discussed.
Background
The FTSE 100 posted its first monthly gain in three months, driven by a 7% jump in AstraZeneca after a $1.5 bn restructuring announcement.
Ticker impact
AstraZeneca jumped 7% after announcing a restructuring expected to save $1.5 billion.
upward pressure as investors price in the $1.5 bn cost reduction.
The restructuring is a material, newly disclosed catalyst with a sizable financial impact.
BP rose 0.5% after reporting a record quarterly net profit.
slight upward pressure from earnings beat.
Record profit is a positive earnings surprise but the move is modest.
British American Tobacco rose 1.7% as consumer staples stocks gained.
potential modest upside if sector stays strong.
Move is driven by broader sector rally, not a company‑specific event.
Unilever gained 2.1% as consumer staples stocks rose.
limited upside tied to sector performance.
No distinct company news; price move reflects sector dynamics.
Market effects
Pharma sector gains 5.1% on AstraZeneca's restructuring news, boosting related stocks.
FTSE 100 posts first monthly gain in three months, indicating broader UK market recovery.
Positive UK market sentiment may spill over to European equities.
Counterpoint
AstraZeneca's cost‑cutting may signal deeper challenges; investors could be cautious.
Key entities
- companyAstraZeneca
Pharma company announcing $1.5 bn cost‑saving restructuring.
- companyNatWest
Bank reporting weaker interest‑income outlook.




